IGC Pharma, Inc. announced that Divisional Direction of Patents, Mexico, has issued a Granting Office Action (GOA) for its treatment of Alzheimer's disease titled "Method and Composition for Treating CNS Disorder. The Company is optimistic that the success witnessed in Mexico can pave the way for additional approvals in the U.S. and Europe. IGC Pharma is currently progressing a Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer's disease, the most common form of a central nervous system disorder (CNS).

IGC-AD1, the Company's lead therapeutic candidate, is a partial CB1 receptor agonist designed with anti-neuroinflammatory properties to address the underlying neurodegeneration resulting in neuropsychiatric symptoms. IGC Pharma has strategically sought patent protection for the IGC-AD1 formulation in many jurisdictions including the U.S., Europe, Canada, and Mexico. Today's announcement of the issuance of the patent for the drug formulation that targets Central Nervous System (CNS) Disorders marks an important milestone in helping set the stage for potential commercialization. Alzheimer's disease is a global public health issue affecting an increasing number of individuals as the population ages.

According to the Alzheimer's Association, by 2050, nearly 13 million Americans will be grappling with Alzheimer's, and related costs are projected to soar to $1 trillion. The burden extends beyond the individual to families, caregivers, and society at large, with approximately 76% of Alzheimer's patients experiencing neuropsychiatric symptoms such as agitation. IGC-AD1 is designed to potentially revolutionize the treatment of Alzheimer's by improving the quality of life of millions of individuals affected by this devastating disease.

The current Phase 2 trial, alongside future investigations, aims to validate the effectiveness of IGC-AD1 in managing agitation in Alzheimer's and relieving caregiver burden. IGC Pharma is currently pursuing five drug assets targeting the treatment of agitation related to symptoms of Alzheimer's disease. These assets include IGC-AD1, TGR-63, LMP, IGC-1C, and IGC-M3, all of which are currently in different stages of clinical trials and development.